Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech ScientificLFTSF 95 EV-to-EBIT is 22.93 as of Jul. 30, 2026, which is 28% below its 10-year median of 31.64. GuruFocus rates LFTSF with a GF Score™ of 95/100 and a GF Value™ of $0.35. The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, LifeTech Scientific ranks worse than 61.88% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
LifeTech Scientific's Enterprise Value for the quarter that ended in Dec. 2025 was $860.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $27.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific EV-to-EBIT Related Terms
LifeTech Scientific EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LifeTech Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's EV-to-EBIT falls into.
LifeTech Scientific's current Enterprise Value is $622.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $27.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific (LFTSF) has a EV-to-EBIT of 22.93 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LifeTech Scientific and its competitors. This is 28% below median its historical median of 31.64. Over the past decade, LifeTech Scientific's EV-to-EBIT has ranged from 18.94 to 163.44. According to the industry distribution chart, LifeTech Scientific ranks #289 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 61.9%.
Is LifeTech Scientific's EV-to-EBIT too high?
LifeTech Scientific's current EV-to-EBIT of 22.93 is 28% below median its 10-year median of 31.64. Over the past 10 years, this metric has ranged from a low of 18.94 to a high of 163.44. The Medical Devices & Instruments industry median EV-to-EBIT is 18.76. LifeTech Scientific's value of 22.93 is 22.2% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #289 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #289 out of 467 companies for EV-to-EBIT. This places LifeTech Scientific in the lower half of its industry. The industry median EV-to-EBIT is 18.76. LifeTech Scientific's value of 22.93 is 22.2% above this benchmark. Historically, LifeTech Scientific's own EV-to-EBIT has ranged from 18.94 to 163.44 over the past decade. While the company's 10-year median is 31.64 vs. the industry median of 18.76, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.76, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current EV-to-EBIT of 22.93 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current EV-to-EBIT is 22.93, which is 28% below median its own 10-year median of 31.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current EV-to-EBIT of 22.93. The stock's GF Value™ is $0.35, compared to a current price of $0.23 — trading 33.3% below its estimated fair value. The current EV-to-EBIT is 22.93, which is 28% below median its 10-year median of 31.64 and 22.2% above the Medical Devices & Instruments industry median of 18.76. LifeTech Scientific's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current EV-to-EBIT is 22.93 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 33.3% below its estimated GF Value™ of $0.35.
Key valuation signals for LFTSF:
EV-to-EBIT: 22.93 (28% below median its 10-year median of 31.64)
GF Value™: $0.35 vs. price of $0.23 (33.3% below fair value)
Industry Position: 22.2% above the Medical Devices & Instruments median (#289 of 467)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for LFTSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
